The war on cancer is on the verge of getting a number of new weapons. Many of them involve a novel approach known as immunotherapy, in which the body’s own immune system is engaged to fight the cancer.
One emerging immunotherapy treatment, chimeric antigen receptor T-cell (CAR-T) therapy, could be approved this year. CAR-T therapy involves genetically altering a patient’s T-cells — a type of white blood cell — to help the immune system find and kill cancer cells. The modified cells are infused into the patient after they are altered in the lab.
Log in to see the rest of this article and the discussion
Kiplinger Alerts is a subscription-based e-mail and online alert service that helps you make more profitable decisions for your business and investments. You get reliable intelligence and forecasts on more than a dozen factors that affect the economy and are critical to your business and financial success.